Bridgeway Capital Management’s Cogent Biosciences COGT Stock Holding History

Bridgeway Capital Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-39,690	Closed	-$341K	–	1321
2021 Q4	$341K	Hold	39,690	–	–	0.01%	1071
2021 Q3	$334K	Hold	39,690	–	–	0.01%	1131
2021 Q2	$322K	Sell	39,690 -8,379	-17%	-$70.8K	0.01%	1197
2021 Q1	$422K	Buy	48,069 +1,284	+3%	+$12.4K	0.01%	1136
2020 Q4	$525K	Sell	46,785 -715	-2%	-$7.86K	0.01%	939
2020 Q3	$445K	Hold	47,500	–	–	0.01%	945
2020 Q2	$87K	Buy	47,500 +36,250	+322%	+$67.2K	﹤0.01%	1249
2020 Q1	$19K	Hold	11,250	–	–	﹤0.01%	1251
2019 Q4	$32K	Hold	11,250	–	–	﹤0.01%	1288
2019 Q3	$65K	Buy	+11,250	New	+$91.5K	﹤0.01%	1263

Other funds holding COGT

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Bridgeway Capital Management's COGT Position: Q1 2022 in Review

Bridgeway Capital Management sold out of Cogent Biosciences (COGT) in Q1 2022, closing a stake of 39,690 shares — an estimated $341K sold.

Bridgeway Capital Management first reported a position in COGT in Q3 2019 and held it in 10 quarters. The position peaked at $525K in Q4 2020. 87 funds tracked by Wall St. Rank hold COGT as of Q1 2022.

Bridgeway Capital Management reported no remaining Cogent Biosciences position as of Q1 2022 after selling out during the quarter.
Bridgeway Capital Management sold 39,690 Cogent Biosciences shares in Q1 2022, an estimated $341K.
Bridgeway Capital Management first reported a position in Cogent Biosciences in Q3 2019 and held it in 10 quarters.
Bridgeway Capital Management's Cogent Biosciences position peaked at $525K in Q4 2020.
87 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2022.

Based on Bridgeway Capital Management's 13F filing for Q1 2022, filed 16 May 2022.